MedTrace Logo

The Effects of I Quit Ordinary Smoking on the Arterial Wall and Endothelial Glycocalyx Properties of Smokers

NCT03452124 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2020-04-24

No results posted yet for this study

Summary

I quit ordinary smoking (IQOS) is proposed as a bridge to smoking cessation. In this study the investigators will examine its effects on aortic elasticity, glycocalyx integrity, and exhaled carbon monoxide (CO) concentration, both acutely and after 1 month of use.

Conditions

  • Smoking Cessation

Interventions

DEVICE

I quit ordinary smoking (IQOS)

I quit ordinary smoking (IQOS) assisted cessation program

OTHER

Conventional cigarette

Conventional cigarette smoking continuation

Sponsors & Collaborators

  • University of Athens

    lead OTHER

Principal Investigators

  • Ignatios Ikonomidis, MD · Attikon University General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-30
Primary Completion
2020-12-31
Completion
2021-06-30

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03452124 on ClinicalTrials.gov